Das Cancer Fatigue Syndrom – eine Übersicht[*]

Zusammenfassung

Cancer Related Fatigue (CRF) stellt das häufigste Krebs- und Krebstherapie-assoziierte Symptom mit großem Einfluss auf die Lebensqualität dar. Hohen Prävalenzzahlen unter adjuvanter Therapie (70–92%) und in palliativen Erkrankungsstadien sowie eine gehäufte Persistenz auch in krankheitsfreien Intervallen (20–36% nach 1–8 Jahren) stehen immer noch unzureichende Therapieangebote in der alltäglichen medizinischen Versorgung gegenüber. Aufgrund des gehäuften chronischen Verlaufs und der Komplexizität der Beschwerden, wie auch der unzureichenden Therapie von CRF-Patienten, besteht ein großer Bedarf an multimodal konzipierten Rehabilitationsmaßnahmen, welche allerdings ihren Stellenwert erst in klinischen Studien belegen müssen.

Abstract

Cancer Related Fatigue (CRF) is the symptom most commonly associated with cancer and cancer therapy that has a significant impact on quality of life. Prevalence is high during adjuvant therapy (70–92%) as well as palliative stages of the disease, and it frequently persists in the disease free interval too (20–36% after 1–8 years). Treatment options routinely offered in medical care are thus fare largely insufficient. There is ample demand for a concept of multimodal rehabilitating measures, because fatigue often becomes chronic, complaints are frequently complex and there are only limited therapeutic options for CRF patients. Hence, these measures have still to prove their significance in clinical studies.

Cancer Related Fatigue (CRF) - Insomnie - multimodale Therapiekonzepte - Ruhe/Aktivitätsrhythmus

Cancer Related Fatigue (CRF) - insomnia - multimodal therapy concepts - rest/activity-rhythm

Literatur

• 1 NCI . Fatigue (PDQ).  U. S. National Institutes of Health. Accessed 06/24/2009, 2009
• 2 Ahlberg K, Ekman T, Gaston-Johannson F. et al . Assessment and management of cancer-related fatigue in adults.  Lancet. 2003;  362 640-650
• 3 Hjermstad MJ, Fossa SD, Oldervoll L. et al . Fatigue in long-term Hodgkin's Disease survivors: A follow-up study.  J Clin Oncol. 2005;  23 6587-6595
• 4 Brach M, Cieza A, Stucki G. et al . ICF Core Sets for Breast Cancer.  J Rehabil Med. 2004;  44 ((Suppl.)) 121-127
• 5 Ryan JL, Carroll JK, Ryan EP. et al . Mechanisms of cancer-related fatigue.  Oncologist. 2007;  12 (S 01) 22-34
• 6 Dimeo F, Schmittel A, Fietz T. et al . Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment.  Ann Oncol. 2004;  15 1237-1242
• 7 Stone P, Richardson A, Ream E. et al . Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum.  Ann Oncol. 2000;  11 971-975
• 8 Hjermstad MJ, Fossa SD, Oldervoll L. et al . Fatigue in long-term Hodgkin's Disease survivors: A follow-up study.  J Clin Oncol. 2005;  23 6587-6595
• 9 Bower JE, Ganz PA, Desmond KA. et al . Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life.  J Clin Oncol. 2000;  18 743-753
• 10 Ahn SH, Park BW, Noh DY. et al . Health-related quality of life in disease-free survivors of breast cancer with the general population.  Ann Oncol. 2007;  18 173-182
• 11 Dittner A, Wessely S, Brown R. The assessment of fatigue. A practical guide for clinicans and researchers.  J Psychosom Res. 2004;  56 157-170
• 12 Glaus A, Muller S. Measuring fatigue of cancer patients in the German-speaking region: development of the Fatigue Assessment Questionnaire.  Pflege. 2001;  14 161-170
• 13 Kröz M, Zerm R, Reif M. et al . Validation of a German version of the Cancer Fatigue Scale (CFS-D).  European Journal of Cancer Care. 2008;  17 33-41
• 14 Radbruch L, Sabatowski R, Elsner F. et al . Validation of the German version of the brief fatigue inventory.  J Pain Symptom Manage. 2003;  25 449-458
• 15 McElroy JA, Newcomb PA, Titus-Ernstoff L. et al . Duration of sleep and breast cancer risk in a large population-based case-control study.  J Sleep Res. 2006;  15 241-249
• 16 Niemann H, Maschke C. WHO LARES Final report Noise effects and morbidity. WHO; 2004
• 17 Davidson JR, MacLean AW, Brundage MD. et al . Sleep disturbance in cancer patients.  Soc Sci Med. 2002;  54 1309-1321
• 18 Roscoe JA, Morrow GR, Hickok JT. et al . Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment.  Support Care Cancer. 2002;  10 329-336
• 19 Mormont MC, Waterhouse J, Bleuzen P. et al . Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.  Clin Cancer Res. 2000;  6 3038-3045
• 20 Innominato PF, Focan C, Gorlia T. et al . Circadian rhythm in rest and activity: A biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer.  Cancer Res. 2009;  69 4700-4707
• 21 Silberfarb PM, Hauri PJ, Oxman TE. et al . Assessment of sleep in patients with lung cancer and breast cancer.  J Clin Oncol. 1993;  11 997-1004
• 22 Leining MG, Gelber S, Rosenberg R. et al . Menopausal-type symptoms in young breast cancer survivors.  Ann Oncol. 2006;  17 1777-1782
• 23 Bower JE, Ganz PA, Desmond KA. et al . Fatigue in long-term breast carcinoma survivors: A longitudinal investigation.  Cancer. 2006;  106 751-758
• 24 Servaes P, Prins J, Verhagen S. et al . Fatigue after breast cancer and in chronic fatigue syndrome: Similarities and differences.  J Psychosom Res. 2002;  52 453-459
• 25 Poppelreuter M, Weis J, Schmid J. et al . Neuropsychologische Folgestörungen nach adjuvanter Therapie des Mammakarzinoms.  Onkologie. 2006;  12 27-35
• 26 Matsuda T, Takayama T, Tashiro M. et al . Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients – evaluation of appropriate research design and methodology to measure symptoms.  Breast Cancer. 2005;  12 279-287
• 27 Fan HG, Houede-Tchen N, Yi QL. et al . Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.  J Clin Oncol. 2005;  23 8025-8032
• 28 Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction.  Clin Breast Cancer. 2002;  3 (S 03) S84-90
• 29 Groenvold M, Petersen MA, Idler E. et al . Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients.  Breast Cancer Res Treat. 2007;  105 209-219
• 30 Hamann T, Hübner J, Neises M. et al . Studie über das subjektive Rehabilitationsbedürfnis von Patientinnen mit Mammakarzinom. Vol 59 2005; 
• 31 Delbrück H. Krebsnachbehandlung. Berlin-Heidelberg: Springer; 2003
• 32 Hamann T. Das subjektive Rehabilitationsbedürfnis von Frauen mit Brustkrebs [Med.Inaug.Diss]. Hannover: Institut für Physikalische Medizin, Medizinische Hochschule Hannover; 2007
• 33 Hübner J. Lebensqualität und Symptome von Patientinnen mit Mammakarzinom – Abschätzung und Entwicklung eines Rehabilitationsbedarfsscors. Hannover: Klinik für Physikalische Medizin, Medizinische Hochschule Hannover; 2009
• 34 Gutenbrunner C, Hübner J, Hamann T. et al . Rehabilitationsbedarf bei Patientinnen mit Mammakarzinom.  Phys Med Rehab Kuror. 2007;  17 224-225
• 35 Aaronson N. The European Organisation for Research and Treatment of Cancer (EORTC) .Modular Approach to Quality of Life.. Assessment in Oncology. An Up-date. New York Raven Press; 1994
• 36 Bullinger M. Erfassung der gesundheitsbezogenen Lebensqualität mit dem SF-36 Health Survey.  Rehabilitation (Stuttg). 1996;  35 XVII-XXX
• 37 Deck R, Kohlmann T, Raspe H. Erwartungen und Motivation bei Patienten in der medizinischen Rehabilitation.  Z f Gesundheitspsychologie. 1998;  6 101-108
• 38 Muthny F. Wege der Krebsverarbeitung von Krebspatienten und Möglichkeiten von Hilfen. Bad Neuenahr: (zit N Delbrück 2003); 1989
• 39 Herrmann C, Buss U. HADS-D, Hospital Anxiety and Depression Scale- Deutsche Version.. Testdokumentation und Handanweisung. Bern, Göttingen, Toronto, Seattle: Verlag Hans Huber; 1995
• 40 Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population.  Eur J Cancer. 2001;  37 1345-1351
• 41 Carroll JK, Kohli S, Mustian KM. et al . Pharmacologic treatment of cancer-related fatigue.  Oncologist. 2007;  12 (S 01) 43-51
• 42 Kallich JD, Tchekmedyian NS, Damiano AM. et al . Psychological outcomes associated with anemia-related fatigue in cancer patients.  Oncology (Huntingt). 2002;  16 ((9 Suppl 10)) 117-124
• 43 Straus DJ, Testa MA, Sarokhan BJ. et al . Quality-of-life and health benefits of early treatment of mild anemia: A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.  Cancer. 2006;  107 1909-1917
• 44 Bohlius J, Schmidlin K, Brillant C. et al . Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials.  Lancet. 2009;  373 1532-1542
• 45 Dimeo FC, Stieglitz RD, Novelli-Fischer U. et al . Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy.  Cancer. 1999;  85 2273-2277
• 46 Spiegel D, Bloom JR, Kraemer HC. et al . Effect of psychosocial treatment on survival of patients with metastatic breast cancer.  Lancet. 1989;  2 888-891
• 47 Carlson LE, Ursuliak Z, Goodey E. et al . The effects of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients: 6-month follow-up.  Support Care Cancer. 2001;  9 112-123
• 48 Bruera E, Valero V, Driver L. et al . Patient-controlled methylphenidate for cancer fatigue: A double-blind, randomized, placebo-controlled trial.  J Clin Oncol. 2006;  24 2073-2078
• 49 Piao BK, Wang YX, Xie GR. et al . Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.  Anticancer Res. 2004;  24 303-309
• 50 Semiglazov VF, Stepula VV, Dudov A. et al . Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: A randomised, placebo-controlled, double-blind, multicentre clinical trial.  Anticancer Res. 2006;  26 1519-1529

1 Die Autoren danken Dagmar Brauer für die grafische Darstellung der Abbildungen und die Mitarbeit an der Erstellung des Manuskriptes. Diese Arbeit wurde vom Humanus-Institut, Institut für Altersforschung und der Software AG-Stiftung gefördert.

Korrespondenzadresse